Xeris Biopharma Q2 revenue rises 34%, slightly beats estimates

Xeris Biopharma Holdings

06/08/2026 12:30

Overview
U.S. biopharmaceutical firm's Q2 net product revenue grew 34% yr/yr, slightly beating analyst expectations
Company tightened full-year 2026 revenue guidance to $385–$390 mln
All 2028 Convertible Notes eliminated, reducing debt and issuing shares

Outlook
Xeris tightens 2026 total revenue guidance to $385 mln to $390 mln
Company expects Recorlev investments to drive growth in H2 2026

Result Drivers
RECORLEV DEMAND - Co said revenue growth was primarily driven by increased patient demand for Recorlev
PRODUCT MIX - Gross margin improved due to favorable product mix dynamics
COMMERCIAL INVESTMENT - Co said strategic investments in Recorlev earlier in the year are gaining traction

Company press release: ID:nBw5zlwmna

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
Slight Beat*
$91.004 mln
$90.23 mln (6 Analysts)
Q2 Loss Per Share
 
$0.18
 
Q2 Net Loss
 
$31.10 mln
 
Q2 Operating Income
 
$5.17 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Xeris Biopharma Holdings, Inc. is $10.00, about 23.3% above its August 5 closing price of $8.11
The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 33 three months ago

Reuters Recommended Reads
Aug 3 - Crinetics Q2 revenue jumps on PALSONIFY launch, withdraws guidance
Aug 5 - Mirum Pharmaceuticals Q2 sales rise, lifts outlook
Aug 5 - Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)